請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68059
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃德富(Huang, Tur-Fu) | |
dc.contributor.author | Yu-Chun Hung | en |
dc.contributor.author | 洪幼軍 | zh_TW |
dc.date.accessioned | 2021-06-17T02:11:57Z | - |
dc.date.available | 2018-02-22 | |
dc.date.copyright | 2018-02-22 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2018-01-04 | |
dc.identifier.citation | 第一部份
1. Huang T. F., Holt C. J., Lukasiewicz H. and Niewiarowski S. Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb/IIIa complex. J. Biol. Chem. 1987; 262: 16157–16163. 2. Marcinkiewicz C. Applications of snake venom components to modulate integrin activities in cell-matrix interactions. Int J Biochem Cell Biol. 2013; 45: 1974-86. 3. Lu Q, Clemetson JM, Clemetson KJ. Snake venoms and hemostasis. J Thromb Haemost. 2005; 3: 1791-9. 4. Huang TF. What have snakes taught us about integrins? Cell Mol Life Sci. 1998; 54: 527–40. 5. Desgrosellier J S, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10: 9-22. 6. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004; 5: 816-826. 7. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007; 7: 678–689. 8. LB Ivashkiv. Cross-regulation of signaling by ITAM-associated receptors. Nature immunology. 2009; 10: 340 –347. 9. Simon L. Goodman, Martin Picard. Integrins as therapeutic targets. Trends in Pharmacological Sciences. 2012; 33: 405-412. 10. Weerasinghe D, McHugh KP, Ross FP, Brown EJ, Gisler RH, Imhof BA. A role for the alphavbeta3 integrin in the transmigration of monocytes. J Cell Biol. 1998; 142: 595–607. 11. Richard O. Hynes. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110: 673–687, 12. Gianni, T. & Campadelli-Fiume, G. The epithelial αvβ3-integrin boosts the MYD88-dependent TLR2 signaling in response to viral and bacterial components. PLoS Pathog. 2014; 10: e1004477. 13. Karin, M., and Greten, F.R. NF-kB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005; 5: 749–759. 14. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest. 2007; 117: 1175-1183. 15. Legate KR, Montañez E, Kudlacek O, Fässler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol. 2006; 7: 20-31. 16. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007; 7: 179-190. 17. Akira, S., Uematsu, S., and Takeuchi, O. Pathogen recognition and innate immunity. Cell. 2006; 124: 783–801. 18. Karin, M., and Greten, F.R. NF-kB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005; 5: 749–759. 19. Akira, S. and Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004; 4, 499–511 20. O'Neill LA, Bowie AG. The family of five: TIR-domain containing adaptors in Toll-like receptor signaling. Nat Rev Immunol. 2007; 7: 353-364. 21. Xu XR, Carrim N, Neves MA, McKeown T, Stratton TW, Coelho RM, Lei X, Chen P, Xu J, Dai X, Li BX, Ni H. Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Thromb J. 2016;14(Suppl 1): 29: 37-46. 22. Alan D. Michelson, Deepak L. Bhatt. How I use laboratory monitoring of antiplatelet therapy? Blood. 2017; 130: 713-721. 23. Li, Z., Yang, F., Dunn, S., Gross, A. K. & Smyth, S. S. Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res. 2011; 127: 184–188. 24. Huang TF, Hsu CC, Kuo YJ. Anti-thrombotic agents derived from snake venom proteins. Thromb J. 2016; 14: 18. 25. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332: 1553-9. 26. Van Amersfoort ES, van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003; 16: 379–414. 27. Shaun P. Jackson. The growing complexity of platelet aggregation. Blood. 2007; 109: 5087-5095. 28. Hsu CC, Chuang WJ, Chang CH, Tseng YL, Peng HC, Huang TF. Improvements in endotoxemic syndromes using a disintegrin, rhodostomin, through integrin αvβ3-dependent pathway. J Thromb Haemost. 2011; 9: 593-602. 29. Sheu JR, Hung WC, Wu CH, Ma MC, Kan YC, Lin CH, Lin MS, Luk HN, Yen MH. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation. 1999; 99: 3056–3062. 30. Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. Am J Health Syst Pharm. 2009; 66: 1089–1096. 31. Gerold G, Abu Ajaj K, Bienert M, Laws HJ, Zychlinsky A, de Diego JL. A Toll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol. 2008; 9: 761–768. 32. Hsu CC, Chuang WJ, Chung CH, Chang CH, Peng HC, Huang TF. Snake venom disintegrin inhibits the activation of toll-like receptors and alleviates sepsis through integrin alphaVbeta3 blockade. Sci Rep. 2016; 6: 23387. 33. Tseng YL, Peng HC, Huang TF. Rhodostomin, a disintegrin, inhibits adhesion of neutrophils to fibrinogen and attenuates superoxide production. J Biomed Sci. 2004; 11: 683-691. 34. Kuo YJ, Chen YR, Hsu CC, Peng HC, Huang TF. An αIIbβ3 antagonist prevents thrombosis without causing FcγRIIa-mediated thrombocytopenia. J Thromb Haemost. 2017; 15: 2230-2244. 35. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005; 115: 3378-3384. 36. Etzioni A, Doerschuk CM, Harlan JM. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood. 1999; 94: 3281-8. 37. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001; 86: 746-756. 38. Briaud SA, Ding ZM, Michael LH, Entman ML, Daniel S, Ballantyne CM. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. American Journal of Physiology - Heart & Circulatory Physiology. 2001; 280: H60-67. 39. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke. 2003; 34: 1790-1795. 40. Cura FA, L’Allier PL, Kapadia SR. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001; 88: 124– 128. 41. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016; 15: 173-183. 42. Dhalla NS, Elmoselhi AB, Hata T, et al. Status of myocardial antioxidants in ischaemia-reperfusion injury. Cardiovasc Res. 2000; 47: 446–456. 43. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357: 1121–1135. 44. Brian Estevez, Bo Shen, Xiaoping Du. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015; 35: 24-29. 45. Alexander Zarbock, Renata K. Polanowska-Grabowska, Klaus Ley. Platelet-neutrophil-interactions: Linking hemostasis and inflammation. Blood Reviews. 2007; 21: 99–111. 46. Legate KR, Montañez E, Kudlacek O, Fassler R. Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nat Rev Mol Cell Biol. 2006; 7: 20-31. 47. J. Jamasbi, K. Ayabe, S. Goto, B. Nieswandt, K. Peter, W. Siess. Platelet receptors as therapeutic targets: Past, present and future. Thromb Haenost. 2017; 117: 1249-1257. 48. Jackson SP. Arterial thrombosis—insidious, unpredictable and deadly. Nat Med. 2011; 17: 1423-1436. 49. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997; 17: 528 –535. 50. Frangogiannis NG. Chemokines in ischaemia and reperfusion. Thromb Haemost. 2007; 97: 738–747. 51. Nikolaos G. Frangogiannis, MD. The inflammatory response in myocardial injury, repair and remodeling. Nat Rev Cardiol. 2014; 11: 255–265. 52. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet–leuleukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999; 34: 1420–1426. 53. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357: 2482-2494. 54. L. Maximilian BujaT. Myocardial ischemia and reperfusion injury. Cardiovascular Pathology. 2005; 14: 170–175. 55. Eltzschig HK, Eckle T. Ischemia and reperfusion from mechanism to translation. Nat Med. 2011; 17: 1391-1401. 56. Bledzka K, Smyth SS, Plow EF. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res. 2013; 112: 1189–1200. 57. Timmers L, Sluijter PGJ, Van Keulen JK, Hoefer IE, Nederhoff MGJ, kGoumans MJ. Toll-like receptor 4 mediated mal adaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008; 102: 257–264. 58. Topol EJ. GUSTO V. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet GPIIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357: 1905 –1914. 59. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998; 98: 2695-2701. 60. Soraya H, Clanachan AS, Rameshrad M, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur J Pharmacol. 2014; 737: 77–84. 61. Helluin O, Chan C, Vilaire G, Mousa S, DeGrado WF, Bennett JS. The activation state of alphavbeta3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem. 2000; 275: 18337-18343. 62. Thiruma V. Arumugam, Eitan Okun, Sung-Chun Tang, John Thundyil. Stephen M. Taylor, Trent M. Woodruff. Toll-like receptors in ischemia-reperfusion injury. Shock. 2009; 32: 4-16. 63. Y Yang, J Lv, S Jiang, Z Ma, D Wang, W Hu, C Deng, C Fan, S Di, Y Sun and W Yi. The emerging role of Toll-like receptor 4 in myocardial Inflammation. Cell Death Dis. 2016; 7: e2234. doi: 10.1038/cddis. 2016.140. 64. Wang C, Sun H, Song Y, Ma Z, Zhang G, Gu X et al. Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-kappaB signaling pathway. Int J Clin Exp Med. 2015; 8: 1737–1746. 65. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X. Protection against myocardial ischemia/ reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase dependent mechanism. J Immunol. 2007; 178: 7317–7324. 66. T. Ha, L. Liu, J. Kelley, R. Kao, D. Williams, C. Li. Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid. Redox Signal. 2011; 15: 1875–1893. 67. Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M. & Fässler, R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat. Med. 2008; 14: 325–330. 68. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004; 61: 498 –511. 69. Coller BS. Binding of abciximab to αVβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost . 1999; 82: 326-336. 70. Baron JH, Moiseeva EP, de Bono DP, Abrams KR, Gershlick AH. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 fab (abciximab): a possible mechanism for influencing restenosis. Cardiovasc Res. 2000; 48: 464-472. 71. Molero L, López-Farré A, Mateos-Cáceres PJ, Fernández-Sánchez R, Luisa Maestro M, Silva J, Rodríguez E, Macaya C. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol. 2005; 146: 419-424. 72. Hohmann JD, et al. Delayed targeting of CD39 to activated platelet gpIIb/IIIa via a single-chain antibody: Breaking the link between antithrombotic potency and bleeding? Blood. 2013; 121: 3067–3075. 73. Li J, et al. RUC-4: A novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014; 34: 2321–2329. 74. Shen B, et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature. 2013; 503: 131–135. 75. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007; 115: 2323-2330. 76. Hsu CC, Chuang WJ, Chung CH, Chang CH, Peng HC, Huang TF. Improved antithrombotic activity and diminished bleeding side effect of a PEGylated alphaIIbbeta3 antagonist, disintegrin. Thromb Res. 2016; 143: 3–10. 77. Lisa K. Jennings. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009; 102: 248–257. 78. Jean-Pierre Bassand. Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology. 2013; 163: 5–18. 79. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010; 30: 2341-2349. 第二部份 1. Antonov, A.S., Antonova, G.N., Munn, D.H., Mivechi, N. Alpha V beta 3 integrin regulates macrophage inflam inflammatory responses via PI3 Kinase/Akt-dependent NF-kappa B activation. J. Cell Physiol. 2011; 226: 469–476. 2. Ao, L.H., Zou, N., Cleveland, J.C., Fullerton, D.A., Meng, X.Z. Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol-Heart C.2009; 297: H21-H28. 3. Ardeshna, K.M., Pizzey, A.R., Devereux, S., Khwaja, A., The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood. 2000; 96: 1039–1046. 4. Arner, E.C., Tortorella, M.D. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergises with interleukin-1. Arthritis Rheum.1995; 38: 1304–1314. 5. Barja-Fidalgo, C., Coelho, A.L., Saldanha-Gama, R., Helal-Neto, E., Mariano-Oliveira, A., Freitas, M.S. Disintegrins: integrin selective ligands which activate integrin-coupled signaling and modulate leukocyte functions. Braz. J. Med. Biol. Res. 2005; 38: 1513-1520. 6. Bedke, J., Kiss, E., Behnes, C.L., Popovic, Z.V., Heuser, M., Stojanovic, T., Sijmonsma, T., Huber, P., Domhan, S., Muschal, S., Abdollahi, A., Gretz, N., Grone, H.J. Anti-inflammatory effects of alphav integrin antagonism in acute kidney allograft rejection. Am. J. Pathol. 2007; 171: 1127–1139. 7. Bertolini, A., Ottani, A., Sandrini, M., 2002. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr. Med. Chem. 2002; 9: 1033–1043. 8. Bhattacharyya, A., Pathak, S., Datta, S., Chattopadhyay, S., Basu, J., Kundu, M. Mitogen-activated protein kinases and nuclear factorkappa B regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem. J. 2002; 368: 121-129. 9. Chen, B.C., Chen, Y.H., Lin, W.W. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced NOS 2 and COX-2 expression in J774 macrophages. Immunology. 1999; 97: 124-129. 10. Chen, H.C., Appeddu, P.A., Isoda, H., Guan, J.L. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 1996; 271: 26329–26334. 11. Chetty, C., Lakka, S.S., Bhoopathi, P., Rao, J.S. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int. J. Cancer. 2009; 124: 2468–2477. 12. Clark, E.A., Brugge, J.S., 1995. Integrins and signal transduction pathways: the road taken. Science. 1995; 268: 233-239. 13. Coelho, A.L., De Freitas, M.S., Mariano-Oliveira, A., Rapozo, D.C., Pinto, L.F., Niewiarowski, S., Zingali, R.B., Marcinkiewicz, C., Barja-Fidalgo, C. RGD- and MLD-disintegrins, jarastatin and EC3, activate integrinmediated signaling modulating the human neutrophils chemotaxis, apoptosis and IL-8 gene expression. Exp. Cell Res. 2004; 292: 371–384. 14. Coelho, A.L., De Freitas, M.S., Mariano-Oliveira, A., Oliveira-Carvalho, A.L., Zingali, R.B., Barja-Fidalgo, C. Interaction of disintegrins with human neutrophils induces cytoskeleton reorganization, focal adhesion kinase activation, and extracellular-regulated kinase-2 nuclear translocation, interfering with the chemotactic function. FASEB. J. 2001; 15: 1643-1645. 15. Curtis, M.J., Hancox, J.C., Farkas, A., Wainwright, C.L., Stables, C.L., Saint, D.A., Clements-Jewery, H., Lambiase, P.D., Billman, G.E., Janse, M.J., Pugsley, M.K., Ng, G.A., Roden, D.M., Camm, A.J., Walker, M.J. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013; 139: 213-248. 16. Dal Secco, D., Paron, J.A., de Oliveira, S.H.P., Ferreira, H., Silva, J.S., Cunha, F.D.Q. Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and induces apoptosis. Nitric Oxide-Biol Ch. 2003; 9: 153-164. 17. Eltzschig, H.K., Collard, C.D. Vascular ischaemia and reperfusion injury. Br Med Bull. 2004; 70: 71-86. 18. Fallach, R., Shainberg, A., Avlas, O., Fainblut, M., Chepurko, Y., Porat, E., Hochhauser, E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. Journal of Molecular and Cellular Cardiology. 2010; 48: 1236-1244. 19. Furundzija, V., Fritzsche, J., Kaufmann, J., Meyborg, H. IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling. Biochem. Biophys. Res. Commun. 2010; 394: 786–791. 20. Gawaz, M., Neumann, F.J., Dickfeld, T., Reininger, A., Adelsberger, H., Gebhardt, A., Schomig, A. Vitronectin receptor (αVβ3) mediates platelet adhesion to the luminal aspect of endothelial cells - Implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-1818. 21. Gerold, G., Ajaj, K.A., Bienert, M., Laws, H.J., Zychlinsky, A., de Diego, J.L. A Toll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat. Immunol. 2008; 9: 761-768. 22. Guo, H., Cai, C.Q., Schroeder, R.A., Kuo, P.C. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J. Immunol. 2001: 166: 1079–1086. 23. Harburger, D.S., Calderwood, D.A., 2009. Integrin signalling at a glance. J. Cell Sci. 2009; 122: 159–163. 24. Howell, K.W., Meng, X., Fullerton, D.A., Jin, C., Reece, T.B., Cleveland, J.C.Jr. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J. Surg. Res. 2011; 171: E27–E31. 25. Karin, M., Delhase, M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 2000; 12: 85-98. 26. Kim, J.H., Kim, D.H., Baek, S.H., Lee, H.J., Kim, M.R., Kwon, H.J., Lee, C.H. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NFkappaB and p38 MAP kinase activity in LPS-stimulated RAW 264.7 cells. Biochem. Pharmacol. 2006; 71: 1198-1205. 27. Kuphal, S., Bauer, R., Bosserhoff, A.K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005; 24: 195–222. 28. Lacy-Hulbert, A., Ueno, T., Ito, T., Jurewicz, M., Izawa, A., Smith, R.N., Chase, C.M., Tanaka, K., Fiorina, P., Russell, P.S., Auchincloss, H. Jr., Sayegh, M.H., Hynes, R.O., Abdi, R., 2007. Beta 3 integrins regulate lymphocyte migration and cytokine responses in heart transplant rejection. Am. J. Transplant. 2007; 7: 1080–1090. 29. LeBel, C.P., Ischiropoulos, H., Bondy, S.C., 1992. Evaluation of the probe 2’,7’- dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992; 5: 227-231. 30. Lee, C.Y., Huang, C.Y., Chen, M.Y., Lin, C.Y., Hsu, H.C., Tang, C.H. IL-8 increases integrin expression and cell motility in human chondrosarcoma cells. J. Cell Biochem. 2011; 112: 2549–2557. 31. Lee, H.S., Moon, C., Lee, H.W., Park, E.M., Cho, M.S., Kang, J.L. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. J. Immunol. 2007; 179: 7001–7011. 32. Li, Q., Verma, I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002; 2: 725–734. 33. Liu, C.Z., Hur, B.T., Huang, T.F., 1996. Measurement of glycoprotein IIb-IIIa blocked by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrin. Thromb. Haemost. 1996; 76: 585–591. 34. Mancuso, G., Midiri, A., Beninati, C., Piraino, G., Valent, A., Nicocia, G., Teti, D., Cook, J., Teti, G. Mitogen-activated protein kinases and NFkappa B are involved in TNF-alpha responses to group B streptococci. J. Immunol. 2002; 169: 1401–1409. 35. Marcinkiewicz, C., Taooka, Y., Yokosaki, Y., Calvete, J.J., Marcinkiewicz, M.M., Lobb, R.R., Niewiarowski, S., Sheppard, D. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin. J. Biol. Chem. 2000; 275: 31930-31937. 36. Moon, C., Han, J.R., Park, H.J., Hah, J.S., Kang, J.L., 2009. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir. Res. 2009; 10: 1-18. 37. Mozaffari, M.S., Schaffer, S.W., 2008. Myocardial ischemic-reperfusion injury in a rat model of metabolic syndrome. Obesity (Silver Spring) 2008; 16: 2253-2258. 38. Nathan, C., Xie, Q.W., 1994. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994; 78: 915–918. 39. Oyama, J., Blais, C., Liu, X.L., Pu, M.Y., Kobzik, L., Kelly, R.A., Bourcier, T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004; 109: 784-789. 40. Park, K.H., Rubin, L.E., Gross, S.S., Levi, R. Nitric-Oxide Is a Mediator of Hypoxic Coronary Vasodilatation - Relation to Adenosine and Cyclooxygenase-Derived Metabolites. Circ Res. 1992; 71: 992-1001. 41. Perera, P.Y., Mayadas, T.N., Takeuchi, O., Akira, S., Zaks-Zilberman, M., Goyert, S.M., Vogel, S.N. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol inducible gene expression. J. Immunol. 2001; 166: 574–581. 42. Rezkalla, S.H., Kloner, R.A. No-reflow phenomenon. Circulation. 2002; 105: 656-662. 43. Rout, U.K., Wang, J., Paria, B.C., Armant, D.R. alpha 5 beta 1, alpha V beta 3 and the platelet-associated integrin alpha IIb beta 3 coordinately regulate adhesion and migration of differentiating mouse trophoblast cells. Dev Biol. 2004; 268: 135-151. 44. Schmedtje, J.F., Ji, Y.S., Liu, W.L., DuBois, R.N., Runge, M.S. Hypoxia induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 1997; 272: 601–608. 45. Scholtes, V.P., Versteeg, D., de Vriest, J.P.M., Hoefer, I.E. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. Clin. Sci. 2011; 121: 205–214. 46. Schofield, Z.V., Woodruff, T.M., Halai, R., Wu, M.C.L., Cooper, M.A., 2013. Neutrophils-a Key Component of Ischemia-Reperfusion Injury. Shock. 2013; 40: 463-470. 47. Shishido, T., Nozaki, N., Yamaguchi, S., Shibata, Y., Nitobe, J., Miyamoto, T., Takahashi, H., Arimoto, T., Maeda, K., Yamakawa, M., Takeuchi, O., Akira, S., Takeishi, Y., Kubota, I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003; 108: 2905-2910. 48. Singh, B., Janardhan, K.S., Kanthan, R. Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis. Exp. Lung Res. 2005; 31: 771-782. 49. Su, H.H., Chu, Y.C., Liao, J.M., Wang, Y.H., Jan, M.S., Lin, C.W., Wu, C.Y., Tseng, C.Y., Yen, J.C., Huang, S.S., 2017. Phellinus linteus Mycelium Alleviates Myocardial Ischemia-Reperfusion Injury through Autophagic Regulation. Front Pharmacol. 2017; 8: 175-186. 50. Surh, Y.J., Chun, K.S., Cha, H.H., Han, S.S., Keum, Y.S., Park, K.K., Lee, S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappaB activation. Mutat. Res. 2001; 480-481: 243–268. 51. Tsai, I.H., Wang, Y.M., Lee, Y.H., 1994. Characterization of a cDNA encoding the precursor of platelet aggregation inhibitor and metalloproteinase from Trimeresurus mucrosquamatus venom. Biochimica Biophysica Acta. 1994; 1200: 337-340. 52. Yeh, C.H., Peng, H.C., Yang, R.S., Huang, T.F. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v) beta(3) blockade of endothelial cells. Mol. Pharmacol. 2001; 59: 1333–1342. 53. Yen, Y.T., Liao, F., Hsiao, C.H., Kao, C.L., Chen, Y.C., Wu-Hsieh, B.A. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006; 80: 2684–2693. 54. Yeh, Y.Y., Chiao, C.C., Kuo, W.Y., Hsiao, Y.C., Chen, Y.J., Wei, Y.Y., Lai, T.H., Fong, Y.C., Tang, C.H. TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NFkappaB- dependent pathway in human chondrosarcoma cells. Biochem. Pharmacol. 2008; 75: 1292–1301. 55. Uwe, S. Anti-inflammatory interventions of NF-kB signaling: potential applications and risks. Biochem. Pharmacol. 2008; 75: 1567–1579. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68059 | - |
dc.description.abstract | 蛇毒蛋白目前已經廣泛的被研究與應用在生命科學各種不同的領域;這些成分能夠直接與細胞作用,並可參與不同的作用機轉進而造成不同的細胞反應導致活化或阻斷細胞生理功能。然而,毒蛇中有許多不同的毒性成份,這些蛇毒蛋白經由純化後可以專一性的結合到受體並調節細胞功能;研究這些蛇毒蛋白的結構和活性的關係,不只可以作為研究工具更可以發展成為新的應用與治療策略;例如,我們研究一種由臺灣龜殼花 (Trimeresurus mucrosquamatus) 分離出的 disintegrin,trimucrin,在調節吞噬細胞功能的作用與免疫反應;而本論文利用純化自臺灣龜殼花中具有抗血小板活性的蛇毒蛋白研究其抗發炎與減少心肌缺血性再灌注損傷之作用機轉,並期望在臨床應用上成為藥物的研究策略。
眾所週知,敗血症常會引起敗血性休克和多重器官衰竭並造成病人死亡,然而治療策略仍然有限;在抗發炎研究中,我們給予內毒素(endotoxin) 例如脂多醣 (LPS) 以誘發急性發炎反應,並且評估抗黏著蛇毒蛋白 trimucrin 在抗發炎反應以及對酯多醣 (LPS) 活化吞噬細胞的作用機轉;然而,抗黏著蛇毒蛋白 trimucrin 除了抗血小板活性的作用以外,目前已經發現具有抗發炎作用,但其作用機轉仍不清楚;在本研究中,我們報導 trimucrin,一種由臺灣龜殼花中純化的蛇毒蛋白,它可以有效的抑制經由脂多醣 (LPS) 刺激人類單核球細胞株 (THP-1) 以及巨噬細胞株 (RAW264.7) 所引發的發炎反應;trimucrin 也可以降低發炎前趨物質細胞激素 (cytokine),包括 TNF-α、IL-6、NO (Nitric oxide) 及 ROS 的釋放,並且抑制經由 LPS 活化的細胞附著 (adhesion) 與移行 (migration) 作用;同時,trimucrin 亦可以明顯的阻斷 NFκB 下游相關發炎物質包括 iNOS 及 COX-2 的表現;此外,我們發現 trimucrin 抗發炎之分子作用機轉是與 MAPK (包括 ERK1/2、JNK 和 p38) 磷酸化降低有關聯性;而 trimucrin 也可以呈現濃度相關性的抑制在 LPS 刺激下誘導產生的 FAK、PI3K、Akt 磷酸化、p65 核轉移、細胞質 IκB 釋放,而可以反轉 NFκB 的 DNA 結合活性;另外,在細胞與受體結合試驗方面,流式細胞儀分析顯示標示有螢光染劑 FITC 之 trimucrin 可以呈現濃度相關性的結合到細胞受體,而 anti-αVβ3 的單株抗體也可以專一性的抑制螢光染劑 FITC 與 trimucrin 形成之複合物結合到細胞 αVβ3 受體;這些結合試驗證實了在人類單核球細胞 (THP-1) 及巨噬細胞 (RAW264.7),αVβ3 是 trimucrin 的結合受體;總而言之,在 LPS 刺激吞噬細胞下,trimucrin 可以降低發炎反應是經由阻斷 MAPK 及 NFκB 的活化而抑制 iNOS 與 NO 的表現。 血小板引起之血栓在急性心肌梗塞之病理反應中扮演一種很重要的角色,在缺血性再灌注損傷之後,血小板在微循環中也可以引起冠狀動脈之血栓性阻塞並導致加速心肌缺血之傷害。眾所週知,disintegrins 是一種具有特定小分子胺基酸序列 RGD 之蛇毒蛋白的總稱。其藉由阻斷 αIIbβ3 integrin,進而抑制血小板的凝集作用;先前研究發現,出血性蛇毒蛋白在血管中經由影響血球,血管和血中蛋白而產生不同的病理反應;此外,disintegrins 能專一性的影響細胞與細胞以及細胞與細胞外間質的作用,某些蛇毒蛋白已經成功的被用來發展成抗血小板、抗血栓或抗血管新生藥物。在本研究中,我們利用血小板凝集器與流式細胞儀,我們發現蛇毒蛋白 trimucrin可以特異性的結合到血小板受體上並抑制血小板的活化與凝集;然而,trimucrin,這一種含有特定序列的 RGD ”小分子” disintegrin,目前已經證實經由阻斷血小板 αIIbβ3 及吞噬細胞的 αVβ3 integrin,並且具有抗血小板凝集及抗發炎作用;在本實驗中,我們給予 trimucrin 後由大鼠取出富含血小板之血漿,證實可以有效抑制在 ADP 刺激下的血小板凝集;此外,我們想證明在大鼠的心肌缺血性灌注傷害下,trimucrin 是否具有心臟保護作用,在大鼠接受了60分鐘的左側冠狀動脈梗塞,並經歷三小時的血流再灌注,大白鼠靜脈給予trimucrin,並且進行缺血性再灌注引發的心律不整以及心肌梗塞的大小比較,trimucrin 明顯的減少了缺血性再灌注引發的心律不整以及死亡率,並且降低了梗塞的體積、肌鈣蛋白 (troponin-I)及乳酸脫氫酶 (lactate dehydrogenase) 活性;此外,在缺血性再灌注損傷之後,trimucrin 也可以改善心臟功能並提升存活率;在體外試驗中,trimucrin 可以呈現濃度相關性的抑制血小板附著到覆蓋有膠質 (collagen) 及纖維蛋白原 (fibrinogen) 的表面;因此,在心臟組織中,trimucrin 可以有意義的降低了缺血性再灌注所引起之嗜中性白血球浸潤 (neutrophil infilitration);此外,給予 trimucrin 可以明顯的減少細胞凋亡蛋白包括 Bax、Caspase-3 的表現,以及增加抗凋亡蛋白 Bcl-2 的表現;這些結果證明了 trimucrin 可以降低心肌缺血性再灌注損傷,可能起因於其抗血小板、抗發炎、以及抗細胞凋亡作用,並進而改善心臟功能。 在本論文中,trimucrin 的發現為蛇毒蛋白在抑制血球細胞間的作用上提供一種新的角色,亦即未來它或許有潛力能應用為抗發炎或是心臟血管保護作用藥物;研究開發蛇毒抗發炎成分亦是未來努力的方向。總之,在探討抗血栓蛇毒蛋白對吞噬細胞以及心臟缺血性灌注損傷的影響之模式中,我們期望能開發以抗發炎理論為基礎的心臟血管保護作用劑或是抗發炎藥物可以提供一種具有潛力的藥理研究方向。 | zh_TW |
dc.description.abstract | Snake venom proteins have been broadly investigated and applied in the numerous areas of life science. These compounds can directly interact with cells in eliciting cellular responses including the activation or blockade of cellular physiological functions. However, some snakes contain some specific components which bind to their respective receptors in regulating cellular biological functions. According to the studies of their structure and activity relationship, we can not only use them as the research tool but also develop the new application and therapeutic strategy. In this study, we investigated the effect of trimucrin, a disintegrin isolated from the venom of Trimeresurus mucrosquamatus which originally was found to inhibit platelet aggregation. We further study its mechanisms of anti-inflammation and attenuating myocardial I-R injury.
As we know, sepsis always causes lots of death due to septic shock and multiple organs failure, but the development of therapeutic strategy for sepsis has been restricted. In the anti-inflammatory study, we used endotoxin such as LPS to induce the acute inflammatory responses, and evaluated the effects of trimucrin in anti-inflammatory responses and investigated the mechanism on LPS-stimulated phagocytes. However, in addition to antiplatelet activity, disintegrin has been demonstrated to exert the anti-inflammatory effect but the possible mechanism is still unclear. In this study, we investigated if trimucrin exhibits anti-inflammatory activity on LPS-induced responses in THP-1 and RAW 264.7 cells. Trimucrin decreases the release of pro-inflammatory cytokines including TNF-α, IL-6, IL-1β and IL-8, nitric oxide, reactive oxygen species (ROS) as well as inhibiting adhesion and migration of LPS-stimulated phagocytes. Trimucrin also significantly attenuates the expression of NFκB-related downstream inducible enzymes like iNOS and COX-2. In addition, we observed that the molecular mechanism of trimucrin-mediated anti-inflammation is associated with decreasing phosphorylation of MAPK molecules including ERK1/2, JNK and p38. Furthermore, trimucrin also inhibits LPS-induced phosphorylation of FAK, PI3K and Akt in a concentration- dependent manner. Trimucrin also reverses NF-κB DNA binding activity via suppressing LPS-induced translocation of p65 into nucleus and cytosolic release of IκB. In cellular binding assay, the flowcytometric analysis showed that FITC-trimucrin bound to cells in a concentration-dependent manner. The anti-αVβ3 mAb also specifically reduced the binding of FITC-conjugated trimucrin. Binding assays demonstrated that integrin αVβ3 was the binding site for trimucrin on THP-1 and RAW 264.7 cells. In conclusion, we showed that trimucrin reduces the inflammatory reaction through inhibition of iNOS expression and NO production by blockade of MAP Kinase and NF-kB activation in LPS-stimulated phagocytes. Platelet-induced thrombus formation plays an important role in the pathological responses of acute myocardial infarction (AMI). Platelets also induce thrombotic occlusion of the coronary artery in microcirculation leading to exacerbating myocardial ischemia following ischemia reperfusion (I-R) injury. Disintegrins are a group of R(K)GD-containing snake venom proteins which inhibit platelet aggregation by blocking αIIbβ3 integrin. The previous reports found that hemorrhagic venom proteins have various pathological responses by influencing blood cells, plasma proteins and vessel wall in cardiovascular system. Furthermore, disintegrins can specifically affect cell-cell and cell-matrix interactions, some disintegrin mimetics have been applied for the anti-platelet, anti-thrombotic and anti-angiogenic agents. However, trimucrin, a novel small-mass RGD-containing disintegrin, has been demonstrated to possess anti-platelet and anti-inflammatory effect through blockade of platelet αIIbβ3 and phagocyte αVβ3 integrin. In this study, we found that the platelet-rich plasma prepared from trimucrin-treated rats showed to diminish platelet aggregation in response to ADP. We tried to determine whether trimucrin is cardioprotective in rats subjected to myocardial ischemia-reperfusion (I-R) injury. The left anterior descending coronary artery of rats was subjected to 1 h occlusion and 3 h reperfusion. The animals were treated with trimucrin intravenously, and the severities of I-R-induced arrhythmia and infarction were compared. Trimucrin significantly reduced I-R-induced arrhythmias and reduced mortality, as well as infarct volume, troponin-I levels, creatine kinase, and lactate dehydrogenase activity. Trimucrin also improved cardiac function and survival rates after I-R injury. In addition, trimucrin concentration-dependently inhibited platelet adhesion on collagen- and fibrinogen-coated surfaces. Trimucrin also significantly reduced neutrophil infiltration into heart tissues after I-R injury. Furthermore, trimucrin treatment caused significant downregulation of Bax, Caspase-3 apoptotic proteins and upregulation of anti-apoptotic Bcl-2 protein. These results demonstrate that trimucrin exerts cardioprotective property against myocardial I-R injury mediated through antiplatele, anti-inflammatory, anti-apoptotic mechanism, as well as improvements in cardiac function. In summary, based on the anti-inflammatory effects of anti-thrombotic venom proteins on phagocytes and myocardial I-R injury, these findings may provide a potentially pharmacological approach for the development of anti-inflammatory and cardiovascular protective agents. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:11:57Z (GMT). No. of bitstreams: 1 ntu-106-D96443003-1.pdf: 5896877 bytes, checksum: 0f8f5e1ae16c9d7d46803ceb20451696 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | Abbreviation ……………………………….…..…………….…………..…..…. 1
Abstract in Chinese…………………..…………….……..………….......… 5 Abstract in English ……………..…………..……….…………....…..…….. 9 CHAPTER 1 Introduction ………………………………………………………….…….….…….. 15 CHAPTER 2 Disintegrin, trimucrin, suppresses LPS-induced activation of phagocytes primarily through blockade of NFkB and MAPK activation ………………… 97 CHAPTER 3 Trimucrin, an RGD containing disintegrin, attenuates myocardial ischemia-reperfusion injury in murine by inhibiting platelet function………...….…. 139 CHAPTER 4 Conclusion and perspectives ……..………………………………...…..………173 References …………….…..…………….…………...………………….….....179 Publication list …………………..…….……………………….....…………189 | |
dc.language.iso | en | |
dc.title | 蛇毒抗黏著蛋白 trimucrin 抑制脂多醣活化吞噬細胞及對抗心臟缺血再灌注損傷機轉之研究 | zh_TW |
dc.title | Mechanism of action of a disintegrin, trimucrin in suppressing LPS-induced activation of phagocytes and
attenuating myocardial ischemia-reperfusion injury | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 鄧哲明(Teng, Che-Ming),顏茂雄(Yen, Mao-Hsiung),楊春茂(Yang, Chuen-Mao),吳文彬(Wu, Wen-Bin) | |
dc.subject.keyword | 蛇毒,抗黏著蛋白,醣蛋白IIb/IIIa,脂多醣,抗發炎,缺血再灌注損傷,心肌梗塞, | zh_TW |
dc.subject.keyword | snake venom,disintegrin,GPIIb/IIIa,LPS,anti-inflammation,ischemia-reperfusion injury,myocardial infarction, | en |
dc.relation.page | 190 | |
dc.identifier.doi | 10.6342/NTU201704512 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-01-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 5.76 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。